Mechanisms induced by carnosic acid in different cancer models (in-vivo), (NA, Not available)
| Cancer type | Animal models | Treatment concentrations | Mechanism of action | References |
|---|---|---|---|---|
| HCC |
MHCC97-H inoculated mice Bel7402 inoculated mice |
10 and 20 mg/kg | NA | Tang et al., 2016 |
| CRC | AOM-induced high-fat diet mice | 0.01-0.02% | Inhibition of Akt | Kim et al., 2014 |
| Breast cancer | MCF-7 inoculated mice | 30 mg/kg | Activation of Caspase-3 | Han et al., 2017 |
| Lung cancer |
HCC827 inoculated mice H358 inoculated mice |
30 mg/kg | Activation of TRAIL/Caspase pathway | Shi et al., 2017 |
| Cisplatin Resistant Lewis Lung cancer Mice | 10 mg/kg | Inhibition of Myeloid-Derived suppressor cells | Wen et al., 2018 | |
| Prostate cancer | 22Rv1 inoculated mice | 100 mg/kg | Decreased expression of AR | Petiwala et al., 2016 |
| Oral cancer |
CAL27 inoculated mice SCC9 inoculated mice |
20 mg/kg | Induction of Mitochondrial apoptotic pathway | Min et al., 2021 |
| Melanoma | B16F10 inoculated mice | 50 mg/kg | Enhance BCNU- and CCNU anti-tumor effect | Lin et al., 2018 |
| Leukemia | K562/A02 inoculated NOD/SCID mice | 1 % (V/V) | NA | Wang et al., 2015 |